1. H Döhner, DJ Weisdorf, and CD Bloomfield. Acute Myeloid Leukemia. 373, 1136- 1152 (2015).
2. S Barjesteh van Waalwijk van Doom-Khosrovani, C Erpelinck, WL van Putten, . High EVI1 expression predicts poor survival in acute myeloid leukemia: a study of 319 de novo AML patients. Blood. 101, 837-845 (2003).
3. PJ Valk, RG Verhaak, MA Beijen, CA Erperlinck, S Barjesteh van Waalwijk van Doom-Khosrovani, JM Boer, HB Beverloo, MJ Moorhouse, PJ van der Spek, B Löwenberg, R Delwel. Prognostically useful gene-expression profiles in acute myeloid leukemia. N Engl J Med. 350, 1617-1628 (2004).
4. S Lugthart, E van Drunen, Y van Norden, A van Hoven, CA Erpelinck, PJ Valk, HB Beverloo, B Löwenberg, R Delwel. High EVI1 levels predict adverse outcome in acute myeloid leukemia: prevalence of EVI1 overexpression and chromosome 3q26 abnormalities underestimated. Blood. 111, 4329-4337 (2008).
5. S Groschel, S Lugthart, RF Schlenk, PJ Valk, K Eiwen, C Goudswaard, WJ van Putten, S Kayser, LF Verdonck, M Lübbert, GJ Ossenkoppele, U Germing, I Schmidt- Wolf, B Schlegelberger, J Krauter, A Ganser, H Döhner, B Löwenberg, K Döhner, R Delwel. High EVI1 expression predicts outcome in younger adult patients with acute myeloid leukemia and is associated with distinct cytogenetic abnormalities. J Clin Oncol. 28, 2101-2107 (2010).
6. E Papaemmanuil, M Gerstung, L Bullinger, VI Gaidzik, P Paschka, ND Roberts, NE Potter, M Heuser, F Thol, N Bolli, G Gundem, PV Loo, I Martincorena, P Ganly, L Mudie, S McLaren, S O’Meara, K Raine, DR Jones, JW Teague, AP Butler, MF Greaves, A Ganser, K Döhner, RF Schlenk, H Döhner, and PJ Campbell. Genomi Classification and Prognosis in Acute Myeloid Leukemia. N Engl J Med. 375, 2023- 2036 (2016).
7. YZ Qin, T Zhao, HH Zhu, J Wang, JS Jia, JS Jia, YY Laai, XS Zhao, HX Shi, YR Liu, H Jiang, XJ Huang, and Q Jiang. High EVI1 Expression Predicts Poor Outcomes in Adult Acute Myeloid Leukemia Patients with Intermediate Cytogenetic Risk Receiving Chemotherapy. Med Sci Monit. 24, 758-767 (2018).
8. D Grimwade, RK Hills, AV Moorman, H Walker, S Chatters, AH Goldstone, K Wheatley, CJ Harrison, and AK Burnett. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significace of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood 116, 354-365 (2010).
9. Z Hu, S Hu, C Ji, Z Tang, B Thakral, S Loghavi, LJ Medeiros, W Wang. 3q26/EVI1 rearrangement in myelodysplastic/myeloproliferative neoplasms: An early event associated with a poor prognosis. Leuk Res 65, 25-28 (2018).
10. SH Swerdlow, E Campo, NL Harris, ES Jaffe, SA Pileri, H Stein, J Thiele, DA Arber, RP Hassejian, MM Le Beau, A Orazi, and R Siebert. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, Revised 4th Edition. 138-139 (2018).
11. S Katayaa, M Suzuki, A Yamaoka, N Keleku-Lukwete, F Katsuoka, A Otsuki, S Kure, JD Engel, and M Yamamoto. Blood. 130, 908-919 (2017).
12. H Yamazaki, M Suzuki, A Otsuki, R Shmizu, EH Bresnick, JD Engel and M Yamamoto. A Remote GATA2 Hematopoietic Enhancer Drives Leukemogenesis in inv(3)(q21;q26) by Activating EVI1 Expression. Cancer Cell. 25, 415-427 (2014).
13. A Yoshimi, S Goyama, N Watanabe-Okochi, Y Yoshiki, Y Nannya, E Nitta, S Arai, T Sato, M Shimabe, M Nakagawa, Y Imai, T Kitamura, and M Kurokawa. Evi1 represses PTEN expression and activities PI3K/AKT/mTOR via interactions with polycomb proteins. Blood. 31, 3617-3628 (2011).
14. E Ayoub, MP Wilson, KE Mcgrath, AJ Li, BJ Frisch, J Palis, LM Calvi, Y Zhang, and AS Perkins. EVI1 overexpression reprograms hematopoiesis via upregulation of Spi1 transcription. Nature Communications. 9, 4239-4250 (2018).
15. M Kurokawa, K Mitani, K Irie, T Matsuyama, T Takahashi, S Chiba, Y Yazaki, K Matsumoto, H Hirai. The oncoprotein Evi-1 represses TGF-beta signaling by inhibiting Smad3. Nature. 394, 92-96 (1998).
16. M Kurokawa, K Mitani, T Yamagata, T Takahashi, K Izutsu, S Ogawa, T Moriguchi, E Nishida, Y Yazaki, H Hirai. The evi-1 oncoprotein inhibits c-Jun N-terminal kinase and prevents stress-induced cell death. EMBO J. 19, 2958-2968 (2000).
17. T Tanaka, J Nishida, K Mitani, S Ogawa, Y Yazaki, H Hirai. Evi-1 raises AP-1 activity and stimulates c-fos promoter transactivation with dependence on the second zinc finger domain. J Biol Chem. 269, 24020-24026 (1994).
18. OS Kustikova, A Schwarzer, M Stahlhut, MH Brugman, T Neumann, M Yang, Z Li, A Schambach, N Heinz, S Gerdes, I Roeder, TC Ha, D Steinmann, B Schiegelberger, and C Baum. Activation of Evi1 inhibits cell cycle progression and differentiation of hematopoietic progenitor cells. Leukemia. 27, 1127-1138 (2013).
19. S Goyama, G Yamamoto, M Shimabe, T Sato, M Ichikawa, S Ogawa, S Chiba, M Kurokawa. Evi-1 is a critical regulator for hematopoietic stem cells and transformed leukemia cells. Cell Stem Cell. 3, 207-220 (2008)
20. OS Kustikova, A Schwarzer, M Stahlhut, MH Brugman, T Neumannn, M Yang, Z Li, A Schambach, N Heinz, S Gerdes, I Roeder, TC Ha, D Steinemann, B Schlegelberger, and C Baum. Activation of Evi1 inhibits cell cycle progression and differentiation of hematopoietic progenitor cells. Leukemia. 27, 1127-1138 (2013).
21. TA Konrad, A Karger, H Hacki, I Schwarzinger, I Herbaek, R Wieser. Inducible expression of EVI1 in human myeloid cells causes phenotypes consistent with its role in myelodysplastic syndromes. J Neukoc Biol. 86, 813-822 (2009).
22. N Yamakawa, K Kaneda, Y Saito, E Ichihara, K Morishita. The increased expression of integrin alpha6 (ITGA6) enhances drug resistance in EVI1 (high) leukemia. PLOS ONE. 7, e30706 (2012).
23. K Karakaya, E Herbst, C Ball, H Glimm, A Krämer, H Löffer. Overexpression of EVI1 interferes with cytokinesis and leads to accumulation of cells with supernumerary centrosomes in G0/1 phase. Cell Cycle. 11, 3492-3503 (2012).
24. N Fenouille, CF Bassil, I Ben-Sahra, L Benajiba, G Alexe, A Ramos, Y Pikman, AS Conway, MR Burgess, Q Li, F Luciano, P Auberger, I Galinsky, DJ DeAngelo, RM Stone, Y Zhang, AS Perkins, K Shannon, MT Hemann, A Puissant, K Stegmaier. The creatine kinase pathway is a metabolic vulnerability in EVI1-positive acute myeloid leukemia. Nature Medicine. 23, 301-313 (2017).
25. L Benajiba, G Alexe, A Su, E Raffoux, J Soulier, MT Hemann, O Hermine, R Irzykson, K Stegmaier, A Puissant. Creatine kinase pathway inhibition alters GSK3 and WNT signaling in EVI1-positie AML. Leukemia. doi:10.1038/s41375-018-0291-x. [Epub ahead of print] (2018).
26. MV Liverti, JW Locasale. The Warburg Effect: How Does it Benefit Cancer Cells? Trends Biochem Sci 41, 211-218 (2016).
27. Q Li, P Wei, J Wu, M Zhang, G Li, Y Li, Y Xu, X Li, D Xie, S Cai, K Xie, D Li. The FOXC/FBP1 signaling axis promotes colorectal cancer proliferation by enhancing the Warburg effect. Oncogene doi:10.1038/s41388-018-0469-8 [Epub ahead of print] (2018).
28. YH Wang, WJ Israelsen, D Lee, VWC Yu, NT Jeanson, CB Clish, LC Cantley, MG Vnader Heiden, and DT Scadden. Cell-State-Specific Metabolic Dependency in Hematopoiesis and Leukemogenesis. Cell. 158, 1309-1323 (2014).
29. S Furutachi, H Miya, T Watanabe, H Kawai, N Yamasaki, Y Harada, I Imayoshi, M Nelson, K Nakayama, Y Hirabayashi, Y Gotoh. Slowly dividing neural progenitors are an embryonic origin of adult neural stem cells. Nature neuroscience 18, 657-665 (2105).
30. Y Kanda. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. . Bone Marrow Transplantation. 48, 452-458 (2013).
31. B Li, B Qiu, DSM Lee, ZE Walton, JD Ochocki, LK Mathew, A Mancuso, TPF Gade, B Keith, I Nissim, MC Simon. Fructose-1, 6-bisphosphatase opposes renal carcinoma progression. Nature. 513, 251-255 (2014).
32. C Dong, T Yuan, Y Wu, Y Wang, TWM Fan, S Miriyaa, Y Lin, J Yao, J Shi, T Kang, P Lorkiewicz, D St Clair, MC Hung, BM Evers, BP Zhou. Loss of FBP1 by Snail- Mediated Repression Provides Metabolic Advantages in Basal-like Breast Cancer. Cancer Cell. 23, 316-331 (2013).
33. H Hirata, K Sugimachi, H Komatsu, M Ueda, T Masuda, R Uchi, S Sakimura, S Nambara, T Saito, Y Shinden, T Iguchi, H Eguchi, S Ito, K Terashima, K Sakamoto, M Hirakawa, H Honda, K Mimori. Decreased Expression of Fructose-1, 6- bisphosphatase Associates with Glucose Metabolism and Tumor Progression in Hepatocellular Carcinoma. Cancer Res. 76, 3265-3276 (2016).
34. TY Li, Y Sun, Y Liang, Q Liu, Y Shi, CS Zhang, C Zhang, L Song, P Zhang, X Zhang, X Li, T Chen, HY Huang, X He, Y Wang, YQ Wu, S Chen, M Jiang, C Chen, C Xie, JY Yang, Y Lin, S Zhao, Z Ye, SY Lin, DTy Chiu, SC Lin. ULK1/2 Constitute a Bifurcate Node Controlling Glucose Metabolic Fluxes in Addition to Autophagy. Molecular Cell. 62, 359-370 (2016).
35. LY Chen, CS Cheng, C Qu, P Wang, H Chen, ZQ Meng, Z Chen. CBX3 promotes proliferation and regulates glycolysis via suppressing FBP1 in pancreatic cancer. Biochem and Biophys Res Commun, 500, 691-697 (2018).
36. GG Loots, I Ovcharenko. rVISTA 2.0: evolutionary analysis of transcription factor binding sites. Nucleic Acids Res. 1, W217-221 (Web Server issue) (2004).
37. H Yuasa, Y Oike, A Iwama, I Nishikata, D Sugiyama, A Perkins, ML Muchenski, T Suda, K Morishita. Oncogenic transcription factor Evi1 regulates hematopoietic stem cell proliferation through GATA-2 expression. EMBO J. 24, 1976-1987 (2005).
38. O Warburg. On the Origin of Cancer Cells. Science. 123, 309-314 (1956).
39. MV Liberti and JW Locasale. The Warburg Effect: How Does it Benefit Cancer Cells? Trends Biochem Sci. 41, 211-218 (2016).
40. E Kavanagh, B Joseph. The hallmarks of CDKN1C (p57, KIP2) in cancer. Biochemica et Biophysica Acta. 1816, 50-96 (2011).
41. S Matsuoka, MC Edwards, C Bai, S Parker, P Zhang, A Baldini, JW Harper, SJ Elledge. p57KIP2, a structurally distinct member of the p21CIP1 Cdk inhibitor family, is a candidate tumor suppressor gene. Gene Dev. 9, 650-662 (1995).
42. D Hanahan, RA Weinberg. The hallmarks of cancer. Cell. 100, 57-70 (2000).
43. RJ Jin, Y Lho, Y Wang, M Ao, MP Revelo, SW Hayward, ML Wills, SK Logan, P Zhang, RJ Matusik. Down-regulation of p57Kip2 induces prostate cancer in the mouse. Cancer Res. 68, 3601-3608 (2008).
44. O Riccio, ME van Gijn, AC Bezdek, L Pellegrinet, JH van Es, U Zimber-Strobl, LJ Strobl, T Honjo, H Clevers, F Radtke. Loss of intestinal crypt progenitor cells owing to inactivation of both Notch1 and Notch2 is accompanied by derepression of CDK inhibitors p27Kip1 and p57Kip2. EMBO Rep. 9, 377-383 (2008).
45. Z Wang, AS Azmi, A Ahmad, S Banerjee, S Wang, FH Sarkar, RM Mohammad. TW- 37, a small molecule inhibitor of Bcl-2, inhibits cell growth and induces apoptosis in pancreatic cancer: involvement of Notch-1 signaling pathway. Cancer Res. 69, 2757- 2765 (2009).
46. A Radujkovic, S Dietrich, M Andrulis, A Benner, T Longerich, A Pellagatti, K Nanda, T Giese, U Germing, S Baldus, J Boultwood, AD Ho, P Dreger, T Luft. Expression of CDKN1C in the bone marrow of patients with myelodysplastic syndrome and secondary acute myeloid leukemia is associated with poor survival after conventional chemotherapy. Int J Cancer. 139, 1403-1413 (2016).
47. A Borriello, I Caldarelli, D Bencivenga, V Cucciolla, A Liva, E Usala, P Danise, L Ronzoni, S Perrotta, F Della Ragione. p57Kip2 is a downstream effector of BCR-ABL kinase inhibitors in chronic myelogenous leukemia cells. Carcinogenesis 32, 10- 18 (2011).
48. Y Zhang, S Stehling-Sun, K Lezon-Geyda, SC Juneja, L Coillard, G Chatterjee, CA Wuertzer, F Camargo, AS Perkins. PR-domain-containing Mds1-Evi1 is critical for long-term hematopoietic stem cell function. Blood. 118, 3853-3861 (2011).
49. R Ihaka, and R Gentoleman. R: a language for data analysis and graphics. J Comp Graph Stat. 5, 299-314. (1996).
50. T Farge, E Saland, F de Toni, N Aroua, M Hosseini, R Perry, C Bosc, M Sugita, L Stuani, M Fraisse, S Scotland, C Larrue, H Boutzen, V Feliu, ML Nicolau-Travers, S Cassant-Sourdy, N Broin, M David, N Serhan, A Sarry, S Tavitian, T Kaoma, L Vallar, J Iacovoni, LK Linares, C Montersino, R Castellano, E Griessinger, Y Collette, O Duchamp, Y Barreira, P Hirsch, T Palama, L Gales, F Delhommeau, BH Garmy- Susini, JC Portais, F Vergez, M Selak, G Danet-Desnoyers, M Carroll, C Recher, JE Sarry. Chemotherapy-Resistant Human Acute Myeloid Leukemia cells Are Not Enrichment for Leukemia Stem Cells but Require Oxidative Metabolism. Cancer Discovery. 7, 716-735 (2017).
51. C Glass, C Wuertzer, X Cui, Y Bi, R Davuluri, YY Xial, M Wilson, K Owens, Y Zhang, A Perkins. Global Identification of EVI1 Target Genes in Acute Myeloid Leukemia. PLOS ONE. 8, e67134 (2013).
52. IP Pateras, K Apostolopoulou, K Niforou, A Kotsinas, VG Gorgoulis. p57KIP2: “Kip”ing the Cell under Control. Mol Cancer Res. 7, 1902-1919 (2009).
53. Y Hashimoto, K Kohri, Y Kaneko, H Morisaki, T Kato, K Ikeda, M Nakanishi. Critical Role for the 310 Helix Region of p57KIP2 in Cyclin-dependent Kinase 2 Inhiition and Growth Suppression. Journal of Biological Chemistry. 273(26), 16544-16550 (1998).
54. E Cerami, J Gao, U Dogrusoz, BE Gross, SO Sumer, BA Aksoy, A Jacobsen, CJ Byrne, ML Heuer, E Larsson, Y Antipin, B Reva, AP Goldberg, C Sander, N Schultz. The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data. Cancer Discovery. 2(5), 401-404 (2012).
55. J Gao, BA Aksoy, U Dogrusoz, G Dresdner, B Gross, SO Sumer, Y Sun, A Jacobsen, R Sinha, E Larsson, E Cerami, C Sander, N Schultz. Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal. Science Signaling. 6(269), pl1 (2013).
56. GA Challen, N Boles, KK Lin, MA Goodell. Mouse Hematopoietic Stem Cell Identification And Analysis. Cytometry A. 75(1), 14-24 (2009).
57. MH Lee, I Reynisdottir, J Massague. Cloning of p57KIP2, a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution. Genes and Development. 9:639-649 (1995).
58. A Subramanian, P Tamayo, VK Mootha, S Mukherjee, BL Ebert, MA Gilette, A Paulovich, SL Pomeroy, TR Golub, ES Lander, JP Mesirov. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. PNAS. 102(43), 15545-15550 (2005).
59. VK Mootha, CM Lindgren, KF Eriksson, A Subramanian, S Sihag, J Lehar, P Puigserver, E Carlsson, M Ridderstrale, E Laurila, N Houstis, MJ Daly, N Patterson, JP Mesirov, TR Golub, P Tamayo, B Spiegelman, ES Lander, JN Hirschhorn, D Altschuler, LC Groop. PGC-1 α -responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nature genetics. 34, 267-273 (2003).
60. TW von Geldern, C Lai, RJ Gum, M Daly, C Sun, EH Fry, C Abad-Zapatero. Benzoxazole benzenesulfonamides are novel allosteric inhibitors of fructose-1,6-bisphophatase with a distinct binding mode. Bioorganic and Medicinal Chemistry Letters. 16, 1811-1815 (2006).
61. Q Dang, SR Kasibhatla, W Xiao, Y Liu, J DaRe, F Taplin, KR Reddy, GR Scarlato, T Gibson, PD van Poelje, SC Potter, MD Erion. Fructose-1,6-phosphatase Inhibitors. 2. Design, Synthesis, and Structure – Activity Relationship of a Series of Phosphonic Acid Containing Benzimidazoles that Function as 5’-Adenosinemonophosphate (AMP) Mimics. Journal of Medicinal Chemistry. 53, 441-451 (2010).
62. CL Jones, BM Stevens, A D’Alessandro, JA Reisz, R Culp-Hill, T Nemkov, S Pei, N Khan, B Adane, H Ye, A Krug, D Reinhold, C Smith, J DeGregori, DA Pollyea, CT Jordan. Inhibition of Amino Acid Metabolism Selectivity Targets Human Leukemia Stem Cells. Cancer Cell. 34, 724-740 (2018).
論文の公開元へ
